Taysha Gene Therapies, Inc. (CIK: 0001806310) EDGAR, Information, Filings... CompaniesBIO.Com

Taysha Gene Therapies, Inc.

Mailing address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, Delaware, 75247
Phone
(214) 612-0000
State location
Texas
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Taysha Gene Therapies, Inc. (CIK: 0001806310) is an American company incorporated in the state of Texas. Head office is located at 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, Texas, 75247. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Taysha Gene Therapies, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Stalfort John A III	0001709418	Jun-22-2023	director
Session R.A. II	0001701846	Jun-20-2023	10 percent owner
Astellas Pharma Inc.	0001376684	Oct-21-2022	10 percent owner
Audentes Therapeutics, Inc.	0001628738	Oct-21-2022	10 percent owner
Sepp-Lorenzino Laura	0001777421	Nov-23-2020	director
Reape Kathleen	0001832203	Nov-23-2020	director
Donenberg Phillip B.	0001238120	Sep-23-2020	director
Manning Paul B	0001494695	Sep-23-2020	director, 10 percent owner
Nolan Sean P.	0001569926	Sep-23-2020	director
Nagendran Sukumar	0001665124	Sep-23-2020	director
PRASAD SUYASH	0001679129	Sep-23-2020	officer: CMO and Head of R&D
Alam Kamran	0001793412	Sep-23-2020	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Taysha Gene Therapies, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-095082 (34 Act) Size: 11924 KB	Aug-12-2024	001-39536 241195005
8-K	Document	Current report filing Acc-no: 0001193125-24-198392 (34 Act) Size: 243 KB	Aug-12-2024	001-39536 241194797
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001231919-24-000053 (33 Act) Size: 4 KB	Jul-05-2024	001-39536 241103166
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001231919-24-000052 (33 Act) Size: 4 KB	Jul-05-2024	001-39536 241103165
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001231919-24-000051 (33 Act) Size: 4 KB	Jul-05-2024	001-39536 241103163
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-018515 ( Act) Size: 8 KB	Jul-01-2024
8-K	Document	Current report filing Acc-no: 0001193125-24-169191 (34 Act) Size: 599 KB	Jun-26-2024	001-39536 241074510
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-24-169188 (33 Act) Size: 1894 KB	Jun-26-2024	333-260069 241074479
8-K	Document	Current report filing Acc-no: 0001193125-24-168479 (34 Act) Size: 1369 KB	Jun-26-2024	001-39536 241070562
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-24-168470 (33 Act) Size: 1896 KB	Jun-26-2024	333-260069 241070555
8-K	Document	Current report filing Acc-no: 0001193125-24-163050 (34 Act) Size: 4360 KB	Jun-18-2024	001-39536 241050199
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-015041 ( Act) Size: 8 KB	May-31-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-015040 ( Act) Size: 7 KB	May-31-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-015039 ( Act) Size: 7 KB	May-31-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-015038 ( Act) Size: 7 KB	May-31-2024
8-K	Document	Current report filing Acc-no: 0001193125-24-150323 (34 Act) Size: 150 KB	May-30-2024	001-39536 241005090
8-K	Document	Current report filing Acc-no: 0001193125-24-138253 (34 Act) Size: 228 KB	May-14-2024	001-39536 24944625
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-059555 (34 Act) Size: 9260 KB	May-14-2024	001-39536 24944479
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001193125-24-100817 (34 Act) Size: 578 KB	Apr-18-2024	001-39536 24854564
ARS	Document	Annual report to security holders Acc-no: 0001193125-24-100808 (34 Act) Size: 2078 KB	Apr-18-2024	001-39536 24854529

Recent 20 filings. View all Taysha Gene Therapies, Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Taysha Gene Therapies, Inc. overview
Taysha Gene Therapies, Inc. job
Taysha Gene Therapies, Inc. stock
Taysha Gene Therapies, Inc. ownership
Taysha Gene Therapies, Inc. CEO
Taysha Gene Therapies, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.